Source:http://linkedlifedata.com/resource/pubmed/id/19201475
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2009-11-3
|
| pubmed:abstractText |
Patients with sickle cell disease (SCD) who receive red blood cell (RBC) transfusions have a higher rate of anti-RBC (allo and auto) antibody development than other transfused subjects. We hypothesized that an incidence and/or kinetics of RBC-specific antibody formation in SCD patients is influenced by a linked inheritance of the hemoglobin beta S (HbbetaS) allele and a polymorphism rs660C/T in the neighboring Ro52 gene. We found that 75% of C/T heterozygous and only 30.8% of T/T homozygous patients that developed antibodies were first transfused before the age of five. In addition, there was a significant inverse correlation between time of exposure to antigen or number of transfusions received and the age when T/T patients received first transfusion, indicating progressive development of competence of their immune system. In contrast, this correlation was not observed in patients with C/T genotype. Finally, increased expression of Ro52 was associated with the presence of the T/T genotype. These results suggest that rs660 polymorphism is a marker of efficiency of tolerance induction in early childhood and immune competence development to RBC antigens in SCD patients of pre-teen/teen age.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1872-9142
|
| pubmed:author |
pubmed-author:BarjaktarevicIgorI,
pubmed-author:HoangAlbertA,
pubmed-author:KratovilTonyaT,
pubmed-author:LubanNaomi L CNL,
pubmed-author:MinnitiCaterina PCP,
pubmed-author:StojakovicMilicaM,
pubmed-author:Tatari-CalderoneZohrehZ,
pubmed-author:VollmerAlisonA,
pubmed-author:VukmanovicStanislavS,
pubmed-author:ZhangEdE
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
47
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
64-70
|
| pubmed:meshHeading |
pubmed-meshheading:19201475-Adolescent,
pubmed-meshheading:19201475-Age Factors,
pubmed-meshheading:19201475-Anemia, Sickle Cell,
pubmed-meshheading:19201475-Biological Markers,
pubmed-meshheading:19201475-Child,
pubmed-meshheading:19201475-Child, Preschool,
pubmed-meshheading:19201475-Erythrocyte Transfusion,
pubmed-meshheading:19201475-Erythrocytes,
pubmed-meshheading:19201475-Female,
pubmed-meshheading:19201475-Genotype,
pubmed-meshheading:19201475-Humans,
pubmed-meshheading:19201475-Immune Tolerance,
pubmed-meshheading:19201475-Immunization,
pubmed-meshheading:19201475-Immunocompetence,
pubmed-meshheading:19201475-Isoantigens,
pubmed-meshheading:19201475-Male,
pubmed-meshheading:19201475-Polymorphism, Single Nucleotide,
pubmed-meshheading:19201475-Ribonucleoproteins,
pubmed-meshheading:19201475-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease.
|
| pubmed:affiliation |
Center for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, DC 20010-2970, USA.
|
| pubmed:publicationType |
Journal Article
|